SRPX2 promotes cancer cell proliferation and migration of papillary thyroid cancer

Thyroid cancer is the endocrine tumor with the highest incidence at present. It originates from the thyroid follicular epithelium or follicular paraepithelial cells. There is an increasing incidence of thyroid cancer all over the world. We found that SRPX2 expression level was higher in papillary thyroid tumors than in normal thyroid tissues, and SRPX2 expression was closely related to tumor grade and clinical prognosis. Previous reports showed that SRPX2 could function by activating PI3K/AKT signaling pathway. In addition, in vitro experiments showed that SRPX2 promoted the proliferation and migration of papillary thyroid cancer (PTC). In conclusion, SRPX2 could promote the malignant development of PTC. This may be a potential treatment target for PTC.

Automated summary

Thyroid cancer is the most common endocrine tumor, originating from the thyroid follicular epithelium or follicular paraepithelial cells. The incidence of thyroid cancer is increasing worldwide. Higher expression of SRPX2 is found in papillary thyroid tumors compared to normal thyroid tissues, and its expression is closely related to tumor grade and clinical prognosis. SRPX2 promotes the proliferation and migration of papillary thyroid cancer through the activation of the PI3K/AKT signaling pathway, suggesting it as a potential treatment target for PTC.